Monoclonal antibody targeting the conserved region of the SARS-CoV-2 spike protein to overcome viral variants

Most therapeutic mAbs target the receptor-binding domain (RBD) of the spike protein of SARS-CoV-2. Unfortunately, the RBD is a hot spot for mutations in SARS-CoV-2 variants, which will lead to loss of the neutralizing function of current therapeutic mAbs. Universal mAbs for different variants are ne...

Full description

Bibliographic Details

Published in:	JCI Insight
Main Authors:	Wan-Ling Wu, Chen-Yi Chiang, Szu-Chia Lai, Chia-Yi Yu, Yu-Ling Huang, Hung-Chun Liao, Ching-Len Liao, Hsin-Wei Chen, Shih-Jen Liu
Format:	Article
Language:	English
Published:	American Society for Clinical investigation 2022-04-01
Subjects:	COVID-19 Therapeutics
Online Access:	https://doi.org/10.1172/jci.insight.157597